Put Option Premiums Collapse After MannKind's FDA Victory

Implied volatility fell off a cliff in options on MannKind (MNKD) Wednesday after the company said a U.S. Food and Drug Administration advisory committee recommended approval of its inhaled therapy for diabetes. Option volume surged as the stock jumped by as much as 80% to $7.16.